New Risk • 11h
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CHF29k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF29k free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-CHF565k). Revenue is less than US$1m (CHF7.1k revenue, or US$8.8k). Market cap is less than US$10m (€222.2k market cap, or US$254.2k). Buy Or Sell Opportunity • May 11
Now 68% overvalued after recent price rise Over the last 90 days, the stock has risen 350% to €0.68. The fair value is estimated to be €0.40, however this is not to be taken as a sell recommendation but rather should be used as a guide only. New Risk • Apr 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (2.1% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-CHF554k). Revenue is less than US$1m (CHF23k revenue, or US$29k). Market cap is less than US$10m (€130.7k market cap, or US$153.3k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Buy Or Sell Opportunity • Jan 19
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 40% to €0.30. The fair value is estimated to be €0.38, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Board Change • Aug 29
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director of Marketing & Sales and Director Manfred Totzauer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Jul 02
Full year 2022 earnings released Full year 2022 results: Net income: CHF18.3k (up CHF54.4k from FY 2021). New Risk • Jul 01
New major risk - Revenue and earnings growth Revenue has declined by 89% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (73% average weekly change). Negative equity (-CHF558k). Revenue has declined by 89% over the past year. Revenue is less than US$1m (CHF3.8k revenue, or US$4.3k). Market cap is less than US$10m (€183.0k market cap, or US$199.7k). Minor Risk Latest financial reports are more than 6 months old (reported June 2022 fiscal period end). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director of Marketing & Sales and Director Manfred Totzauer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Jul 10
Full year 2021 earnings released Full year 2021 results: Revenue: CHF15.4k (down 78% from FY 2020). Net loss: CHF36.0k (loss narrowed 24% from FY 2020). Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director of Marketing & Sales and Director Manfred Totzauer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Jun 23
Full year 2020 earnings released The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CHF70.7k (up 14% from FY 2019). Net loss: CHF47.3k (loss widened 316% from FY 2019). Is New 90 Day High Low • Oct 31
New 90-day high: €0.51 The company is up 750% from its price of €0.06 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period. Is New 90 Day High Low • Oct 12
New 90-day high: €0.40 The company is up 567% from its price of €0.06 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. 
